nutra pharma expands licensing

(OTCBB:NPHC), a biotechnology company that is developing drugs for HIV

and Multiple Sclerosis (MS), has today announced that it has expanded

its licensing agreement with NanoLogix, Inc., (Pink Sheets: NNLX) to

include intellectual property for the use of testing the environment

for NonTuberculous Mycobacterium (NTM).

"NTM infections are becoming a major concern for hospitals and medical

clinics around the world," explained Rik J. Deitsch, Chairman and CEO

of Nutra Pharma Corporation. "Combining our newly licensed

intellectual property with our current test kit technology will allow

our subsidiary, Designer Diagnostics, to attempt to successfully

launch a cost-effective solution to help identify the environmental

sources of NTM infections," he added.

NonTuberculous Mycobacterium, also known as atypical Tuberculosis

(Atypical TB) or Mycobacterium other than Tuberculosis (MOTT), is a

bacteria that is found in water, including hot tubs and showers, some

domestic and wild animals, and soil. One of the most common forms of

NTM infections found in humans is Mycobacterium avium complex (MAC).

This is a primary cause of respiratory disease in humans and is a

leading cause of death in HIV/AIDS patients.

"Expanding this licensing agreement to include environmental testing

is a natural progression of our relationship with Nutra Pharma and our

belief in its ability to successfully bring these kits to market,"

commented Bret Barnhizer, President and CEO of NanoLogix, Inc. "In

addition to helping detect NTM in patients, Nutra Pharma will now be

able to test for NTM in the environment to help prevent others from

becoming infected," he concluded.

Nutra Pharma's wholly-owned medical devices subsidiary, Designer

Diagnostics, is currently planning to undergo third party validation

for its NTM diagnostic test kits at leading Tuberculosis research

institute, National Jewish Medical and Research Center, in Denver,

Colorado. The Company plans to apply for FDA approval upon successful

completion of this clinical trial.

Recently, distinguished NTM research scientist, Dr. Rahul Narang, used

the Designer Diagnostics test kits to test soil and water samples

collected from the environment of patients with NTM infections. This

was the first time the technique was used in India and the findings

were presented in November at the 38th Union World Conference on Lung

Health in Cape Town, South Africa.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the

acquisition, licensing and commercialization of pharmaceutical

products and technologies for the management of neurological

disorders, cancer, autoimmune and infectious diseases. Nutra Pharma

Corp. through its subsidiaries carries out basic drug discovery

research and clinical development and also seeks strategic licensing

partnerships to reduce the risks associated with the drug development

process. The Company's holding, ReceptoPharm, Inc, is developing these

technologies for the production of drugs for HIV and Multiple

Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is

engaged in the research and development of diagnostic test kits

designed to be used for the rapid identification of infectious

diseases such as Tuberculosis (TB) and Mycobacterium

avium-intracellulare (MAI). Nutra Pharma continues to identify and

acquire intellectual property and companies in the biotechnology

arena.

http://www.NutraPharma.com

http://www.DesignerDiagnostics.com

SEC Disclaimer

This press release contains forward-looking statements. The words or

phrases "would be," "will allow," "intends to," "will likely result,"

"are expected to," "will continue," "is anticipated," "estimate,"

"project," or similar expressions are intended to identify

"forward-looking statements." Actual results could differ materially

from those projected in Nutra Pharma's ("the Company") business plan.

The Company's business is subject to various risks, which are

discussed in the Company's filings with the Securities and Exchange

Commission ("SEC"). The expanded licensing agreement with NanoLogix,

Inc., to include environmental testing should not be construed as an

indication in any way whatsoever of the value of the Company or its

common stock. The Company's filings may be accessed at the SEC's Edgar

system at www.sec.gov. Statements made herein are as of the date of

this press release and should not be relied upon as of any subsequent

date. The Company cautions readers not to place reliance on such

statements. Unless otherwise required by applicable law, we do not

undertake, and we specifically disclaim any obligation, to update any

forward-looking statements to reflect occurrences, developments,

unanticipated events or circumstances after the date of such

statement.

SOURCE: Nutra Pharma Corp.

Nutra Pharma Corp.

David Isserman, 877-895-5647